Indonesia's Bio Farma Leads Vaccine Self-Reliance Through DCVMN Collaboration

Strategic Insights -

Indonesia's Bio Farma has played a vital role in the Developing Countries Vaccine Manufacturers' Network (DCVMN) since its founding in 2000, driving vaccine self-reliance and public health capacity in developing countries. The company's commitment to collaboration and innovation has resulted in significant achievements, including the development of the nOPV2 vaccine, which received an Emergency Use Listing from the World Health Organization in 2020. Bio Farma's leadership in DCVMN has also led to its recognition as a hub for vaccine collaboration and knowledge-sharing among developing countries.

Key Takeaways:

  • Bio Farma has been a founding member of DCVMN since 2000, with a key driver role in advancing vaccine self-reliance and public health capacity in developing countries.
  • The company hosted the 2nd DCVMN Annual General Meeting in 2001 in Bandung, where the network formalized its structure and governance.
  • Shadiq Akasya, President Director of Bio Farma, emphasized the company's commitment to global health beyond national interests, stating that involvement in DCVMN reflects Indonesia's dedication to contributing to global health security.
  • Bio Farma was a vital contributor to the expansion of access to the pentavalent (DPT-HepB-Hib) vaccine through a technology-transfer collaboration with the Netherlands Vaccine Institute in 2004.
  • Indonesia's global trust in Bio Farma has continued to grow, with the company hosting the 13th DCVMN AGM in Bali in 2012 and serving as Chair of the Board of DCVMN for 2023-2025.
  • Bio Farma's nOPV2 vaccine received an Emergency Use Listing from the WHO in 2020, reflecting the company's scientific and technical excellence.
  • Bio Farma has a production capacity of more than 3.5 billion doses per year, supplying vaccines to over 150 countries and holding WHO Prequalification certification for 12 types of vaccines.
  • The company is the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution, strengthening Indonesia's strategic role in the global health landscape.

Statistics:

  • 46 vaccine manufacturers from 17 developing countries are part of the DCVMN network.
  • Bio Farma has a production capacity of more than 3.5 billion doses per year.
  • The company supplies vaccines to over 150 countries.
  • Bio Farma holds WHO Prequalification certification for 12 types of vaccines.
  • The company is the Center of Excellence for the Organization of Islamic Cooperation (OIC) in vaccine development, production, and distribution.

Sources:

  • Developing Countries Vaccine Manufacturers' Network (DCVMN)
  • PT Bio Farma (Persero)